Airway Therapeutics Raises $50M for Zelpultide Alfa

The help keeping an extremely premature infant alive can also become part of the injury those lungs have to survive. Mechanical ventilation and supplemental oxygen are essential in neonatal intensive care, but fragile, underdeveloped lungs can respond with inflammation and damage that contribute to bronchopulmonary dysplasia, or BPD.

Airway Therapeutics closed a $50M equity round on August 25, 2026, to test whether zelpultide alfa can change that equation. The capital will support the Phase 2b portion of the company's ongoing Phase 2b/3 clinical trial and the chemistry, manufacturing, controls, and analytical work needed to prepare the biologic for a potential regulatory submission.

The round gives Airway a defined proof schedule, not an answer. The therapy remains investigational, the pivotal study has no posted results, and the next disclosed milestone is an interim analysis expected by the end of Q2 2027.

What Airway Therapeutics Raised

The $50M equity round combines 2 pieces of financing. Airway had previously raised $26M through a SAFE, while $24M came through the company's Series E-2. That distinction matters because the announcement is not a fresh $50M Series E-2 check landing on a single day.

Approximately 94% of Airway's existing investors participated in the Series E-2. The company named Cincinnati Children's and a syndicate of large family offices, but it did not identify the family offices, disclose a lead investor, or provide a valuation. Those omissions do not weaken the announcement; they simply mark the line between what the company reported and what the market might be tempted to fill in for it.

The financing follows an $11M Series B announced in 2018 and a $15.5M Series C announced in 2020. Airway did not publish an updated total-capital figure with the new transaction, and historical databases had not yet reconciled the SAFE and Series E-2 structure when this article was prepared.

Why Zelpultide Alfa Matters

Bronchopulmonary dysplasia is a serious lung condition that primarily affects premature newborns. Babies can develop BPD after respiratory distress, infection, inflammation, and prolonged treatment with mechanical ventilation or supplemental oxygen. The same support that helps a newborn survive can become part of the injury that follows.

Airway's lead candidate, zelpultide alfa, is a recombinant form of human surfactant protein D, or SP-D. The company describes SP-D as an immune-modulating protein that helps regulate inflammation, recognize and clear pathogens, and maintain surfactant homeostasis in the lungs. Very premature infants can lack enough of this protein while their lungs are still developing and under the stress of respiratory support.

The therapeutic idea is to replace that missing protection early enough to prevent severe lung disease rather than manage the consequences after BPD has developed. Airway is not merely adding another version of conventional surfactant. It is testing whether a protein with immune and infection-related functions can reduce the incidence of grade 2 or grade 3 BPD or death in infants at high risk.

How the ZELA Trial Tests the Thesis

The ZELA study is a randomized, double-blind, placebo-controlled, multicenter Phase 2b/3 trial with an adaptive design. ClinicalTrials.gov lists estimated enrollment of 366 extremely preterm neonates born between 22 weeks and 27 weeks, 6 days of gestation, subject to additional eligibility requirements.

In Phase 2b, infants are assigned to standard care plus 4 mg/kg zelpultide alfa, standard care plus 6 mg/kg zelpultide alfa, or standard care plus an air-sham comparator. Treatment is delivered intratracheally for up to 7 administrations at 24-hour intervals while the infant remains intubated. The dose-selection stage is intended to identify which regimen should move into the confirmatory Phase 3 portion.

The study's primary outcome is the incidence of grade 2 or grade 3 BPD or death at week 36 postmenstrual age. Secondary measures include ventilator-free days, days on supplemental oxygen, extubation rate, and other indicators of respiratory support. This is a hard clinical endpoint in a fragile population, which is exactly why early signals should not be treated as a finished efficacy story.

Airway says its Phase 1b study demonstrated favorable safety and tolerability. That evidence supported continued development, but the pivotal program must now establish dose, safety, and efficacy at a larger scale. The company expects the interim analysis completing Phase 2b by the end of Q2 2027.

The Manufacturing Clock Runs Beside the Clinical Clock

Drug development coverage often treats manufacturing as administrative work waiting behind the science. For a biologic, chemistry, manufacturing, and controls are part of the product claim. A molecule must be produced consistently, characterized analytically, and documented well enough for regulators to understand what each patient is receiving.

That is why Airway is directing the round toward both trial execution and CMC and analytical activities for BLA readiness. Marc Salzberg, MD, Chairman and CEO, is responsible for moving the clinical program toward dose selection and interim analysis. Alan S. Wolk, CFO and COO, must help ensure the capital also carries the operating and manufacturing package forward.

Those clocks cannot be run one after the other without wasting time. A successful clinical readout with an immature manufacturing package creates a new delay, while a polished CMC file cannot rescue a therapy that misses its endpoint. The $50M is designed to let Airway advance both obligations in parallel.

What the Investor Participation Signals

The approximately 94% participation rate among existing investors is meaningful, but it should be read carefully. It shows that investors already familiar with Airway's history, trial design, and development risk chose to keep financing the program. It does not independently validate the therapy, forecast the interim analysis, or replace data from the ZELA study.

Cincinnati Children's involvement also carries history. Airway was created in 2011 as a spinout from Cincinnati Children's Hospital Medical Center, and the institution's continued participation connects the financing to the original scientific lineage. The unnamed family-office syndicate broadens the capital base, but the disclosure is not specific enough to support claims about any individual investor's strategy.

What Comes Next

Airway Therapeutics now has to turn financing structure into clinical and manufacturing evidence. The immediate work is clear: complete Phase 2b dose selection, reach the planned interim analysis, maintain study execution across a multinational network, and build the analytical package needed for BLA readiness.

The broader opportunity is significant because BPD affects infants whose lungs and immune defenses are still developing. The obligation is equally significant because the proposed therapy enters neonatal intensive care at a moment when every dose, endpoint, manufacturing control, and safety signal matters. Airway has bought runway for the test. The infants, investigators, and manufacturing record will decide whether that runway leads to a preventive therapy.